The proteasome inhibitor bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and peripheral blood mononuclear cells

Cecilia Ceresa*, Elisa Giovannetti*, Jens Voortman, Adrie C Laan, Richard Honeywell, Giuseppe Giaccone and Godefridus J Peters

Submitted

* Equally contributed